The abstract is about the cohort A, stage I of the ongoing global phase ? trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis
The ABDM public dashboard is a one-stop solution for information on the mission’s progress up to state/UT level
The inspection was a Pre-Approval cum cGMP inspection and it covered 15 ANDAs
The company’s annual sales grew from Rs 548.12 crore in FY 2020-21 to Rs 598.65 crore this fiscal
68% of patients receiving Kymriah in the ELARA trial experienced a complete response, with an 86% overall response rate, along with a remarkable safety profile
JB, in its new avatar, emerges as the fastest growing pharmaceuticals company in India
The integration and transition of the brands are expected to be completed by June 2022.
Bempedoic acid helps lower cardiovascular risk in high or very high-risk atherosclerotic cardiovascular disease (ASCVD) patients as an add-on therapy to maximally tolerated statin and/or ezetimibe
Glofitamab has the potential to offer a readily available, fixed-duration CD20xCD3 bispecific antibody treatment approach for people with aggressive lymphoma
The company has posted net loss of Rs. 460.21 crores for the Financial Year ended March 31, 2022.
Subscribe To Our Newsletter & Stay Updated
